Interventional Radiology Imaging

What Is the Next Step for an Enlarging Peripheral Lung Nodule in a High-Risk Patient?

·
What Is the Next Step for an Enlarging Peripheral Lung Nodule in a High-Risk Patient?

A pulmonologist reviews the third serial chest CT for a 74-year-old patient with severe chronic obstructive pulmonary disease (COPD). The solitary solid nodule in the right upper lobe periphery, initially 1.2 cm, has now grown to 1.8 cm over nine months. The patient’s poor pulmonary function makes them a high-risk candidate for surgical resection. The clinical question is clear and urgent: how to obtain a definitive diagnosis to guide non-surgical treatment without subjecting the patient to the risks of an open procedure. This is a common and challenging scenario where interventional radiology plays a pivotal role. For this specific presentation, the American College of Radiology (ACR) Appropriateness Criteria rate Percutaneous lung biopsy as Usually Appropriate, providing a direct path to a tissue diagnosis.

## Who Fits This Clinical Scenario for an Enlarging Peripheral Nodule?

This guidance is specifically for an adult patient presenting with a solitary solid pulmonary nodule that meets a precise set of criteria. The workflow described here applies when the nodule is located in the periphery of the lung, has been observed to be serially enlarging on follow-up imaging, and now measures between 1 and 3 cm in diameter. Critically, this scenario assumes the patient has significant comorbidities—such as severe cardiopulmonary disease, advanced age, or poor functional status—that classify them as having a high risk of poor surgical outcomes.

It is essential to distinguish this presentation from similar but distinct clinical situations that require a different approach:

  • Surgically Fit Patients: This guidance does not apply to patients who are good candidates for surgery. For an enlarging nodule in a low-risk patient, surgical management is often the preferred diagnostic and therapeutic step.
  • Stable Nodules: If a solid nodule has been stable in size for two or more years, even in a person who smokes, the likelihood of malignancy is very low, and continued surveillance or no further follow-up is typically warranted.
  • Central or Hilar Nodules: This workflow is for peripheral nodules. A nodule located centrally, near the hilum or major airways, is often better approached via bronchoscopy with techniques like endobronchial ultrasound (EBUS).
  • Ground-Glass Nodules: The management of subsolid or ground-glass nodules follows a different algorithm, often involving a longer period of surveillance due to their typically slower growth rate.

## What Diagnoses Are You Working Up With an Enlarging Solid Nodule?

When a solid pulmonary nodule demonstrates interval growth, the primary clinical concern is malignancy. The differential diagnosis guides the decision to pursue a tissue diagnosis, as confirming the specific pathology is essential for determining the subsequent treatment plan, especially when surgery is not an option.

The most common and pressing diagnosis to confirm or exclude is primary lung cancer. Non-small cell lung cancer (NSCLC), particularly adenocarcinoma, is the most frequent histology for peripheral solid nodules. The documented growth is a classic feature of malignancy, and obtaining a tissue sample is critical not only for diagnosis but also for molecular testing (e.g., EGFR, ALK, PD-L1), which guides modern systemic therapies.

A solitary pulmonary metastasis is another key consideration, especially if the patient has a known history of a non-pulmonary primary malignancy (e.g., colon, renal, breast cancer, or melanoma). In some cases, a new lung nodule may be the first sign of metastatic disease from a previously treated or occult primary cancer. Differentiating a new primary lung cancer from a metastasis is crucial, as treatment strategies differ significantly.

While less likely for a serially enlarging solid nodule, an infectious or inflammatory process remains on the differential. Organized pneumonia or granulomatous infections, such as those caused by fungi (histoplasmosis, coccidioidomycosis) or mycobacteria (tuberculosis), can present as solitary nodules. These etiologies are more common in endemic regions but should always be considered, as a definitive diagnosis can prevent unnecessary oncologic therapy.

## Why Is Percutaneous Lung Biopsy the Recommended Next Step?

For a peripheral, enlarging solid nodule in a patient who is a poor surgical candidate, obtaining a tissue diagnosis is paramount. The ACR designates Percutaneous lung biopsy as Usually Appropriate because it offers the most direct, minimally invasive, and highest-yield method for achieving this goal in this specific setting.

The procedure, typically performed under computed tomography (CT) guidance, allows an interventional radiologist to precisely target the nodule and obtain core tissue samples. This approach has a high diagnostic accuracy for malignancy in peripheral lesions of this size. The tissue cores are superior to cytology alone, as they preserve tissue architecture and provide sufficient material for immunohistochemistry and molecular profiling, which are now standard of care for managing lung cancer. The peripheral location makes the nodule easily accessible with a needle, minimizing the risk of traversing major vessels or airways.

Alternative procedures are rated lower for clear reasons in this context:

  • Surgical management and Fiducial marker and surgical management are both rated Usually not appropriate. This rating directly reflects the core premise of the clinical scenario: the patient has a high risk of poor surgical outcomes. Subjecting such a patient to the morbidity of a thoracotomy or video-assisted thoracoscopic surgery (VATS) for diagnosis is contraindicated.
  • Endobronchial ultrasound and biopsy (EBUS) is rated May be appropriate. While EBUS is the standard for sampling central lesions and mediastinal lymph nodes, its diagnostic yield for peripheral nodules between 1 and 3 cm is lower than that of CT-guided percutaneous biopsy. The bronchoscope’s reach is limited in the distal lung parenchyma.
  • Follow-up imaging only is also rated May be appropriate, but it is a suboptimal choice. The nodule is already known to be enlarging, a strong indicator of malignancy. Further delay in diagnosis postpones necessary treatment and allows for potential tumor progression and metastasis.

The percutaneous biopsy is performed with CT guidance, which involves ionizing radiation, but the exposure is localized to the chest and targeted to the procedure. No intravenous contrast is typically needed for biopsy guidance.

## What’s Next After Percutaneous Lung Biopsy? Downstream Workflow

The results of the percutaneous biopsy will dictate the subsequent management plan, which revolves around non-surgical treatment options. The workflow diverges based on the pathology report.

  • If the biopsy is positive for primary lung cancer: The patient should be referred for multidisciplinary evaluation by oncology and radiation oncology. For an early-stage NSCLC in a medically inoperable patient, Stereotactic Body Radiotherapy (SBRT) is the standard-of-care treatment and is rated May be appropriate by the ACR as a management option. SBRT delivers highly conformal, ablative doses of radiation with excellent local control rates. Percutaneous thermal ablation (e.g., radiofrequency, microwave) is another option, also rated May be appropriate.
  • If the biopsy is positive for metastasis: The patient should be referred to a medical oncologist to discuss systemic therapy appropriate for the identified primary cancer. The management will be guided by the origin of the metastasis (e.g., chemotherapy for metastatic colon cancer, immunotherapy for melanoma).
  • If the biopsy is negative or non-diagnostic: This result requires careful clinical correlation. A non-diagnostic biopsy may occur due to technical challenges or extensive necrosis within the nodule. If clinical suspicion for malignancy remains high (based on nodule morphology and growth rate), a repeat biopsy may be considered. If the result is definitively benign (e.g., granuloma), a short-interval follow-up CT (e.g., in 3-6 months) can be performed to ensure stability and confirm the benign diagnosis.

## Pitfalls to Avoid (and When to Get Help)

Navigating this scenario requires careful planning to maximize diagnostic yield and patient safety. Here are several common pitfalls to avoid:

  • Ignoring Anticoagulation: Failing to hold anticoagulants or antiplatelet agents appropriately before a percutaneous biopsy significantly increases the risk of bleeding complications, such as pulmonary hemorrhage or hemothorax. Always coordinate medication management with the interventional radiologist and the prescribing clinician.
  • Biopsy Without Reviewing Priors: The interventional radiologist must review all prior imaging to plan the safest and most direct needle trajectory, avoiding fissures, bullae, and vessels. This review also confirms the nodule’s growth and solid components.
  • Accepting a Non-Diagnostic Result at Face Value: If a biopsy is non-diagnostic but the pre-test probability of malignancy is high, do not simply revert to long-term observation. A discussion with the interventional radiologist about the feasibility and risk of a repeat biopsy is warranted.
  • Delaying the Biopsy: For a documented enlarging nodule, time is critical. Unnecessary delays in scheduling the biopsy can allow for tumor progression, potentially limiting treatment options. If you encounter barriers to timely biopsy, escalate to the interventional radiology or pulmonary medicine department leadership.

## Related ACR Topics and Tools

For a comprehensive overview of all clinical variants related to this topic, please consult our parent guide. For further exploration of adjacent scenarios and imaging techniques, the following resources are available:

Frequently Asked Questions

What are the main risks of a percutaneous lung biopsy?

The most common risk is pneumothorax (collapsed lung), which occurs in a significant minority of patients but only requires a chest tube for treatment in a small fraction of those cases. Another primary risk is pulmonary hemorrhage (bleeding around the needle track), which is usually minor and self-limiting. More severe complications are rare but can include air embolism and hemothorax.

Why not just treat with SBRT without a biopsy if malignancy is so likely?

While treating empirically is an option in very select cases (e.g., a patient too frail for even a biopsy), obtaining a tissue diagnosis is strongly preferred. It confirms malignancy, preventing the unnecessary irradiation of a benign lesion (like an infection). It also provides the specific cancer type and molecular markers needed to guide systemic therapy if the disease is or becomes metastatic.

Does the specific peripheral location (e.g., subpleural vs. mid-parenchyma) affect the decision?

Yes, it primarily affects the procedural risk profile. A very subpleural nodule may have a slightly higher risk of pneumothorax but is often very easy to target. A nodule adjacent to a major vessel or the heart requires more careful planning. However, for any peripheral location, CT-guided biopsy remains the preferred diagnostic method over bronchoscopic techniques.

What if the nodule was 4 cm instead of 1-3 cm?

If the lesion is larger than 3 cm, it is classified as a mass rather than a nodule. The diagnostic approach is similar, with percutaneous biopsy remaining a primary tool. However, the pre-test probability of malignancy is even higher, and the biopsy may need to target the solid, enhancing periphery of the mass to avoid a false negative from central necrosis.

If the biopsy shows a benign process like a granuloma, is any further follow-up needed?

Yes. Even with a benign biopsy result, a short-term follow-up CT (e.g., 6 months) is often recommended. This is to ensure there was no sampling error and to confirm that the nodule is stable or resolving, which would be concordant with a benign diagnosis. If the nodule continues to grow despite a benign biopsy, a repeat biopsy or surgical consultation may be necessary.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026